Alnylam Pharmaceuticals Statistics
Total Valuation
ALNY has a market cap or net worth of $28.92 billion. The enterprise value is $28.95 billion.
| Market Cap | 28.92B |
| Enterprise Value | 28.95B |
Important Dates
The last earnings date was Thursday, July 30, 2026, before market open.
| Earnings Date | Jul 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ALNY has 133.81 million shares outstanding. The number of shares has increased by 7.12% in one year.
| Current Share Class | 133.81M |
| Shares Outstanding | 133.81M |
| Shares Change (YoY) | +7.12% |
| Shares Change (QoQ) | +0.04% |
| Owned by Insiders (%) | 0.39% |
| Owned by Institutions (%) | 100.68% |
| Float | 133.24M |
Valuation Ratios
The trailing PE ratio is 40.70 and the forward PE ratio is 26.62.
| PE Ratio | 40.70 |
| Forward PE | 26.62 |
| PS Ratio | 6.09 |
| Forward PS | 4.55 |
| PB Ratio | 22.59 |
| P/TBV Ratio | 21.62 |
| P/FCF Ratio | 35.70 |
| P/OCF Ratio | 32.10 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 27.45, with an EV/FCF ratio of 35.31.
| EV / Earnings | 37.37 |
| EV / Sales | 6.03 |
| EV / EBITDA | 27.45 |
| EV / EBIT | 28.96 |
| EV / FCF | 35.31 |
Financial Position
The company has a current ratio of 3.05, with a Debt / Equity ratio of 2.21.
| Current Ratio | 3.05 |
| Quick Ratio | 2.79 |
| Debt / Equity | 2.21 |
| Debt / EBITDA | 2.83 |
| Debt / FCF | 3.64 |
| Interest Coverage | 3.52 |
Financial Efficiency
Return on equity (ROE) is 96.55% and return on invested capital (ROIC) is 96.60%.
| Return on Equity (ROE) | 96.55% |
| Return on Assets (ROA) | 12.34% |
| Return on Invested Capital (ROIC) | 96.60% |
| Return on Capital Employed (ROCE) | 24.71% |
| Weighted Average Cost of Capital (WACC) | 5.94% |
| Revenue Per Employee | $1.92M |
| Profits Per Employee | $309,884 |
| Employee Count | 2,500 |
| Asset Turnover | 0.95 |
| Inventory Turnover | 11.58 |
Taxes
| Income Tax | -8.42M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -48.41% in the last 52 weeks. The beta is 0.28, so ALNY's price volatility has been lower than the market average.
| Beta (5Y) | 0.28 |
| 52-Week Price Change | -48.41% |
| 50-Day Moving Average | 281.97 |
| 200-Day Moving Average | 344.20 |
| Relative Strength Index (RSI) | 32.64 |
| Average Volume (20 Days) | 2,305,501 |
Short Selling Information
The latest short interest is 5.77 million, so 4.31% of the outstanding shares have been sold short.
| Short Interest | 5.77M |
| Short Previous Month | 5.80M |
| Short % of Shares Out | 4.31% |
| Short % of Float | 4.33% |
| Short Ratio (days to cover) | 3.62 |
Income Statement
In the last 12 months, ALNY had revenue of $4.80 billion and earned $774.71 million in profits. Earnings per share was $5.62.
| Revenue | 4.80B |
| Gross Profit | 3.83B |
| Operating Income | 999.78M |
| Pretax Income | 766.29M |
| Net Income | 774.71M |
| EBITDA | 1.05B |
| EBIT | 999.78M |
| Earnings Per Share (EPS) | $5.62 |
Balance Sheet
The company has $3.31 billion in cash and $2.99 billion in debt, with a net cash position of $320.66 million or $2.40 per share.
| Cash & Cash Equivalents | 3.31B |
| Total Debt | 2.99B |
| Net Cash | 320.66M |
| Net Cash Per Share | $2.40 |
| Equity (Book Value) | 1.35B |
| Book Value Per Share | 10.13 |
| Working Capital | 3.11B |
Cash Flow
In the last 12 months, operating cash flow was $911.81 million and capital expenditures -$91.95 million, giving a free cash flow of $819.87 million.
| Operating Cash Flow | 911.81M |
| Capital Expenditures | -91.95M |
| Depreciation & Amortization | 54.76M |
| Net Borrowing | -546.95M |
| Free Cash Flow | 819.87M |
| FCF Per Share | $6.13 |
Margins
Gross margin is 79.65%, with operating and profit margins of 20.81% and 16.13%.
| Gross Margin | 79.65% |
| Operating Margin | 20.81% |
| Pretax Margin | 15.95% |
| Profit Margin | 16.13% |
| EBITDA Margin | 21.95% |
| EBIT Margin | 20.81% |
| FCF Margin | 17.07% |
Dividends & Yields
ALNY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.12% |
| Shareholder Yield | -7.12% |
| Earnings Yield | 2.65% |
| FCF Yield | 2.80% |
Analyst Forecast
The average price target for ALNY is $375.76, which is 73.87% higher than the current price. The consensus rating is "Buy".
| Price Target | $375.76 |
| Price Target Difference | 73.87% |
| Analyst Consensus | Buy |
| Analyst Count | 28 |
| Revenue Growth Forecast (3Y) | 31.64% |
| EPS Growth Forecast (3Y) | 45.21% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ALNY has an Altman Z-Score of 7.58 and a Piotroski F-Score of 6.
| Altman Z-Score | 7.58 |
| Piotroski F-Score | 6 |